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Abstract
Background: Point-of-care CD4 tests at HIV diagnosis could improve linkage to care in resource-limited settings. Our
objective is to evaluate the clinical and economic impact of point-of-care CD4 tests compared to laboratory-based tests in
Mozambique.
Methods and Findings: We use a validated model of HIV testing, linkage, and treatment (CEPAC-International) to examine
two strategies of immunological staging in Mozambique: (1) laboratory-based CD4 testing (LAB-CD4) and (2) point-of-care
CD4 testing (POC-CD4). Model outcomes include 5-y survival, life expectancy, lifetime costs, and incremental cost-
effectiveness ratios (ICERs). Input parameters include linkage to care (LAB-CD4, 34%; POC-CD4, 61%), probability of correctly
detecting antiretroviral therapy (ART) eligibility (sensitivity: LAB-CD4, 100%; POC-CD4, 90%) or ART ineligibility (specificity:
LAB-CD4, 100%; POC-CD4, 85%), and test cost (LAB-CD4, US$10; POC-CD4, US$24). In sensitivity analyses, we vary POC-CD4-
specific parameters, as well as cohort and setting parameters to reflect a range of scenarios in sub-Saharan Africa. We
consider ICERs less than three times the per capita gross domestic product in Mozambique (US$570) to be cost-effective,
and ICERs less than one times the per capita gross domestic product in Mozambique to be very cost-effective. Projected 5-y
survival in HIV-infected persons with LAB-CD4 is 60.9% (95% CI, 60.9%–61.0%), increasing to 65.0% (95% CI, 64.9%–65.1%)
with POC-CD4. Discounted life expectancy and per person lifetime costs with LAB-CD4 are 9.6 y (95% CI, 9.6–9.6 y) and
US$2,440 (95% CI, US$2,440–US$2,450) and increase with POC-CD4 to 10.3 y (95% CI, 10.3–10.3 y) and US$2,800 (95% CI,
US$2,790–US$2,800); the ICER of POC-CD4 compared to LAB-CD4 is US$500/year of life saved (YLS) (95% CI, US$480–
US$520/YLS). POC-CD4 improves clinical outcomes and remains near the very cost-effective threshold in sensitivity analyses,
even if point-of-care CD4 tests have lower sensitivity/specificity and higher cost than published values. In other resource-
limited settings with fewer opportunities to access care, POC-CD4 has a greater impact on clinical outcomes and remains
cost-effective compared to LAB-CD4. Limitations of the analysis include the uncertainty around input parameters, which is
examined in sensitivity analyses. The potential added benefits due to decreased transmission are excluded; their inclusion
would likely further increase the value of POC-CD4 compared to LAB-CD4.
Conclusions: POC-CD4 at the time of HIV diagnosis could improve survival and be cost-effective compared to LAB-CD4 in
Mozambique, if it improves linkage to care. POC-CD4 could have the greatest impact on mortality in settings where
resources for HIV testing and linkage are most limited.
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Introduction
In sub-Saharan Africa, over 50% of HIV-infected patients
remain unlinked to clinical care, despite the dramatic scale-up of
HIV treatment over the past decade [1]. Point-of-care technolo-
gies have been widely promoted as a mechanism to improve triage
and linkage of newly diagnosed HIV-infected patients to care [2–
5].
After initial HIV diagnosis, patients undergo immunological
staging, in which the severity of immunosuppression, as quantified
by CD4 count, determines eligibility for antiretroviral therapy
(ART) initiation. Current standard of care throughout sub-
Saharan Africa at the time of HIV diagnosis is a laboratory-based
CD4 test, when available [5]. Patients receive the results of the
CD4 test at a return visit and are triaged to clinical care depending
on their ART eligibility as determined by national policy
guidelines [6]. Patient attrition at each of these steps after HIV
diagnosis is high, ranging from 17% to 80% in resource-limited
settings [7–13]. The World Health Organization (WHO) has
targeted these steps in linkage to care as opportunities for
improvement and has underscored the potential offered by
point-of-care CD4 tests to expedite immunologic staging [5].
Data from multiple regions throughout sub-Saharan Africa
demonstrate that point-of-care CD4 testing (POC-CD4) can
improve overall linkage to care [14–18]. Our objective is to assess
the clinical outcomes and cost-effectiveness of POC-CD4 com-
pared to laboratory-based CD4 testing (LAB-CD4) for immuno-
logic staging in Mozambique and to examine the generalizability
of these results to settings throughout sub-Saharan Africa with a
diversity of opportunities to access care.
Methods
Ethics Statement
This work was approved by the Partners Human Research
Committee, Boston, Massachusetts, US (Protocol #2003
P001019).
Analytic Overview
We use the Cost-Effectiveness of Preventing AIDS Complica-
tions–International (CEPAC-I) model to project the clinical
impact, costs, and cost-effectiveness of POC-CD4 at the time of
HIV diagnosis at outpatient voluntary testing and counseling
(VCT) clinics [19–22]. In a simulated cohort of newly diagnosed
HIV-infected patients in Mozambique, we investigate two
strategies for immunologic staging: LAB-CD4 versus POC-CD4.
The two strategies differ in terms of (1) the probability of linkage to
care, (2) CD4 test sensitivity and specificity, and (3) CD4 test cost.
For each strategy, the model simulates 2 million patients to
produce stable outputs. We use deterministic and probabilistic
sensitivity analyses to examine the generalizability of our results to
sub-Saharan settings with different populations, infrastructures,
and available resources for HIV testing, clinical care, and
retention in care.
We use the model to project 5-y survival, life expectancy (LE),
and per person lifetime direct medical costs of HIV care (in 2011
US dollars). Future benefits and costs are discounted at 3% per
year [23]. We calculate the incremental cost-effectiveness ratio
(ICER) as the ratio of the difference in outcomes between the two
strategies of care (Dcosts/DLE) after immunologic staging [23].
Guided by recommendations from the WHO Commission on
Macroeconomics and Health [24] and WHO-CHOICE [25], we
consider a strategy to be ‘‘cost-effective’’ if its ICER is less than
three times the country-specific per capita gross domestic product
(GDP) (Mozambique 2011 GDP, US$570) and ‘‘very cost-
effective’’ if its ICER is less than one times the per capita GDP
[26].
Model Structure
The CEPAC-I model is a previously published Monte Carlo
state-transition model of HIV natural history, case detection,
linkage, and treatment [19–22].
Cohort characteristics. At the simulation’s start, patients
have just been diagnosed with HIV at a VCT clinic. Their
baseline characteristics are drawn randomly from distributions of
age, gender, CD4 count, and HIV RNA, populated from region-
specific clinical trials and cohort data [14,27]. In each month,
simulated patients move between health states, specified broadly as
chronic HIV infection, acute clinical events, and death. The
simulated cohort excludes incident and acute HIV cases.
Linkage to care. To link to care after HIV diagnosis,
simulated patients must complete a CD4 test for immunological
staging, which determines ART eligibility. Linkage to care
requires completion of three sequential steps: (1) obtaining the
patient sample and completing the CD4 test (‘‘test completion’’),
(2) alerting the patient to the test result (‘‘result receipt’’), and (3)
initiating HIV clinical care after receipt of the immunologic
staging result (‘‘initiating care’’). Based on the ‘‘true CD4 count’’
(in vivo), patients are either ‘‘ART eligible’’ (i.e., true CD4 count
# threshold for ART eligibility) or ‘‘ART ineligible’’ (i.e., true
CD4 count. threshold). The ‘‘observed CD4 count’’ is the test
result given to the patient, which can differ from the true CD4
count depending on CD4 test characteristics. Patients can receive
observed CD4 count results 1 wk or more after HIV diagnosis
(LAB-CD4) or sooner (POC-CD4). For patients who receive their
CD4 test result, the probability of initiating care depends on the
observed CD4 count (Figure 1). Patients who do not initiate care
after immunologic staging (i.e., ‘‘unlinked’’) can link in subsequent
months following an acute opportunistic infection (OI), tubercu-
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staging. Unlinked patients progress with natural history of HIV.
CD4 count for immunologic staging. We use two param-
eters to calculate the observed CD4 count compared to the true
CD4 count: precision and bias. The coefficient of variation (CV)
characterizes precision (i.e., the variability of observed CD4 count
from repeat tests on a single specimen); we calculate the observed
CD4 count as the true CD4 count plus a random draw from a
normal distribution with zero mean and standard deviation (SD)
equal to the product of the CV and the true CD4 count. To
represent any systematic bias of the CD4 test (i.e., if the observed
CD4 count is consistently greater or less than the true CD4 count),
we also vary the mean of the observed CD4 count from the true
CD4 count. For both precision and bias, we use a percentage of
the true CD4 count because variations in the observed CD4 count
will range more widely for higher true CD4 count values [28].
CD4 test sensitivity and specificity depend on three parameters:
the test’s precision and bias, the true CD4 count of the population,
and the ART-eligibility threshold. We use model output for true
and observed CD4 counts to calculate the sensitivity and
specificity associated with an ART-eligibility threshold.
Patients whose ART eligibility is misclassified by the point-of-
care CD4 test are triaged and treated accordingly. If misclassified
as ART eligible (i.e., truly ART ineligible, with true CD4 count.
250/ml but observed CD4 count #250/ml), linked patients initiate
ART, which improves their projected clinical outcomes and
increases costs. Patients misclassified as ART ineligible (i.e., truly
ART eligible, with true CD4 count #250/ml but observed CD4
count.250/ml) do not start ART after linkage and have worse
clinical outcomes. To remain conservative towards potential
benefits of POC-CD4, patients initially misclassified as ART
ineligible are never successfully transitioned to ART.
HIV clinical care. Linked patients are treated with care
concordant with national guidelines in Mozambique according to
the observed CD4 count, including clinical visits, laboratory
monitoring, and ART for eligible patients. ART efficacy depends
on patient adherence; those with better adherence have a greater
probability of virologic suppression and associated immunologic
recovery [29]. To account for interruptions in care after linkage
[30–32], simulated patients have a monthly probability of
becoming lost to follow-up (LTFU), with a probability of returning
to care. When LTFU, patients discontinue ART and co-
trimoxazole prophylaxis and experience HIV natural history.
Input Parameters
Cohort characteristics. We derive cohort characteristics
from a published study of immunologic staging in Mozambique:
mean CD4 count 300/ml (SD, 230/ml), mean age 32.7 y (SD, 10.1
y), and 65% female (Table 1) [14].
Linkage to care. The overall cohort linkage for LAB-CD4 is
34%. This is equivalent to the product of CD4 test completion
(53%), CD4 test result receipt conditional on test completion
(88%), and initiation of care conditional on receiving results (74%).
Because the probability of initiation of care is different for patients
whose observed CD4 count makes them ART eligible (63%) or
ineligible (81%), it is weighted by the proportion of the linked
population that is ART eligible (42%) or ineligible (58%)
(Figure 1; Table 1). In POC-CD4, 61% of the cohort links to
care, with improved CD4 test completion (83%) and result receipt
(99%). Initiation of care occurs in 74%; 68% from the observed
ART-eligible patients and 79% from the ART-ineligible patients,
weighted by the 46% of the population who are ART eligible and
the 54% who are ART ineligible. For rates of initiating care after
receipt of an ART-ineligible CD4 test result, we use unpublished
data collected in the same study protocol as the ART-eligible
linkage rates [14].
For unlinked patients, we estimate that repeat testing occurs at a
monthly rate of once every 10 y, as only 39% of HIV-infected
individuals are estimated to know their HIV status in South Africa,
where HIV testing services are more robust than in Mozambique
[11]. Unlinked patients will link to HIV care 43% of the time if ill
with TB (reported range, 13%–62%) [10,33–35] and 75% of the
time with WHO stage 3/4 OI (Table 1).
CD4 count for immunologic staging. LAB-CD4 uses the
gold standard laboratory CD4 test, assuming perfect performance
characteristics (sensitivity/specificity, 100%/100%) to ensure the
analysis is not biased towards POC-CD4.
POC-CD4 uses an Alere Pima point-of-care CD4 test (Alere,
Waltham, Massachusetts, US). We estimate the point-of-care
CD4 test’s precision at 32.6% CV, as reported from a rural
clinical care setting operated by non-research staff [36], and the
test’s bias at 0% (reported range, 212.3% to +16.5%) [36–38].
The point-of-care CD4 test has a sensitivity of 90% and a
specificity of 85%, when ART eligibility is at CD4 count #250/
ml (Figure 2A).
The laboratory CD4 test is estimated to cost US$10/test in
Mozambique [39], whereas each point-of-care CD4 test costs
US$24 [40]. Estimated test cost includes investments in
equipment amortized over its usable lifetime, costs of materials
to complete each test (including quality controls), and labor. We
use the highest reported test cost from a microcosting approach
[39,40] to ensure that the analysis is not biased towards POC-
CD4.
HIV clinical care. The Mozambique national guidelines
inform inputs regarding patient monitoring, prophylaxis, and
ART initiation at CD4 count #250/ml or a WHO stage 3 or 4
OI, including TB. Biannual laboratory CD4 tests monitor patient
responses to ART; HIV RNA is not available [6]. Following
ART initiation, first-line ART leads to virologic suppression in
79% of patients at 6 mo [29], resulting in rising CD4 counts [41].
Monitoring for ART failure uses immunologic criteria (e.g.,
$50% decrease in CD4 count or a CD4 count below nadir after
$1 y of ART) [42] and prompts a switch to protease inhibitor–
based second-line ART.
Estimates of loss to follow-up are from a systematic review of
sub-Saharan African studies that excludes mortality [32]; we also
correct for those patients who transfer care (i.e., not truly LTFU)
[43]. The probability of LTFU is inversely related to adherence;
patients with better ART adherence have lower LTFU rates
(monthly probability, 0.2%) compared to patients with poorer
adherence (monthly LTFU probability, 1.1%) [44]. Patients who
are LTFU have a monthly probability of returning to care (1.0%)
after being lost for 1 y [45] and return to care 50% of the time
with a WHO stage 3/4 OI or TB. These input parameters result
in 30.0%–34.8% of the cohort experiencing at least one
interruption in HIV care that lasts 2.6 y (SD, 2.3 y) (Table 1).
To assess the model’s internal validity, we compare model output
for LTFU at 36 mo with reported values from the published
literature.
HIV care costs. Linked patients experience routine HIV care
costs independent of initial immunologic staging strategy. We use
costs of routine comprehensive HIV care for patients on ART #6
mo or .6 mo derived from 11 HIV treatment facilities in
Mozambique, including the costs of clinical care, treatment
and prophylaxis for OIs, and laboratory monitoring [46]. Given
the model’s structure, we use current CD4 count as a proxy
for duration of ART (i.e., CD4 count #250/ml for ART #6
mo; CD4 count.250/ml for ART.6 mo). We assume that
Cost-Effectiveness of Point-of-Care CD4 Tests
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comprehensive HIV care. We evaluate the approach by compar-
ing these estimated annual HIV care costs (US$160–US$250/y)
with published primary data from countries with GDP and
available HIV clinical care similar to those of Mozambique
(reported range, US$115–US$338/y) [47–49]. Antiretroviral
medication costs are from the Clinton Health Access Initiative
(Table 1) [50]. All costs are converted to 2011 US dollars [26].
Validation of the Model
We simulate HIV-uninfected individuals in the model to
demonstrate its internal consistency.
Deterministic Sensitivity Analyses
Guided by published literature, we perform one-way sensitivity
analyses for overall linkage by individually varying the probability of
test completion, receipt of CD4 test results, and initiation of care [15–
17,51], and point-of-care and laboratory test characteristics (see
Tables S1–S3) [36–38,52–56]. We vary CD4 test costs to capture the
economies of scale associated with using one machine to complete
more tests per day, as well as the lower labor costs in Mozambique
and other sub-Saharan African countries [57]. We investigate cohort
characteristics (e.g., age, gender, and mean CD4 count at the time of
diagnosis) and features of clinical care (e.g., laboratory monitoring
strategies, LTFU rates, and routine care costs) (Table 1).
Figure 1. Schematic comparing two strategies for immunological staging after HIV diagnosis: LAB-CD4 and POC-CD4. In both LAB-
CD4 and POC-CD4, literature-based probabilities are shown for: completing a laboratory CD4 test, receiving the test result, and successful initiation of
care (Table 1). Probability of linkage depends on ART eligibility as determined by the ‘‘true CD4 count,’’ as well as the ‘‘observed CD4 count’’ test
result (T) [14]. Bolded branches denote where the outcomes result in linkage to care. T+, observed CD4 count #250/ml; T2, observed CD4 count.
250/ml.
doi:10.1371/journal.pmed.1001725.g001
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Regional access to care. We consider the clinical outcomes
and cost-effectiveness of POC-CD4 compared to LAB-CD4 in
four different settings within sub-Saharan Africa to represent a
range of access to repeat HIV testing, staging, and linkage to HIV
care when ill with an acute OI or TB (Table 1).
ART eligibility at CD4 count #350/ml. To examine how
expanded access to ART in Mozambique might affect the
clinical and economic benefits of POC-CD4, we perform a
scenario analysis in which national policy recommends
initiation of ART at CD4 count #350/ml, such as in other
sub-Saharan African countries. Using a CV of 32.6% and 0%
bias [36], point-of-care CD4 tests have a sensitivity of 90% and
specificity of 78% when ART eligibility is at CD4 count #350/
ml( F i g u r e2 B ) .
Probabilistic Sensitivity Analysis
We perform a multi-way probabilistic sensitivity analysis to
evaluate the effect of uncertainty around input parameters in
the model and include all nine parameters for which one-way
sensitivity analyses result in appreciable changes in ICERs. The
model randomly selects a value for each parameter from a
prespecified probability distribution (Table 2) and uses this
combination of parameter values to calculate the expected
clinical outcomes and costs for each strategy. The same process
repeats 10,000 times for each strategy to obtain a distribution of
outcomes and costs for each strategy. We first identify the more
cost-effective strategy for each of the iterations and then assess
the proportion of runs in which each strategy is identified
as more cost-effective within a range of willingness-to-pay
thresholds.
Estimates of Uncertainty
We calculate the 95% confidence interval using model output
for 5-y survival, costs, and life expectancy (undiscounted and
discounted). We use Fieller’s theorem to calculate the 95%
confidence interval for the ICER [58,59].
Programmatic Considerations and Affordability
To investigate the affordability of POC-CD4, we assess the
annual financial outlay associated with POC-CD4 compared to
LAB-CD4 from the perspective of the Mozambique Ministry of
Health (MMOH) and the donors who together provide funding
for Mozambique’s national response to the HIV/AIDS epidemic
[60]. We consider the undiscounted direct costs of the two
strategies for immunologic staging, as well as the costs of guideline-
concordant HIV care incurred by those who link to care (Table 1).
We include all equipment costs for immunologic staging in year
one. We estimate that 120,000 people are newly diagnosed with
HIV infection in the first year of the rollout of this strategy in
Mozambique [61].
Results
Validation of the Model, Including Loss to Follow-Up
When the model simulates HIV-uninfected patients in Mozam-
bique, life expectancy from birth is 54.7 and 58.3 y for males and
females, respectively. This is consistent with WHO-reported
overall life expectancy for Mozambique (i.e., 52.0 and 53.0 y,
respectively), since the WHO estimates include HIV-infected
people [62]. Of the simulated cohort, 10.6% are LTFU at 36 mo,
which is consistent with estimates of 12.0% derived from published
data [32,43].
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Five-year survival with LAB-CD4 is 60.9% (95% CI, 60.9%–
61.0%), which increases to 65.0% (95% CI, 64.9%–65.0%) with
POC-CD4 (Table 3). Discounted life expectancy is 9.6 y (95% CI,
9.6–9.6 y) with LAB-CD4 and increases to 10.3 y (95% CI, 10.3–
10.3 y) with POC-CD4. Per person discounted lifetime costs are
US$2,440 (95% CI, US$2,440–US$2,450) with use of LAB-CD4
and increase to US$2,800 (95% CI, US$2,790–US$2,800) with
POC-CD4, which results in an ICER of US$500/year of life saved
(YLS) in Mozambique. The 95% confidence interval surrounding
the ICER is US$480–US$520/YLS, a value that has interpretable
meaning in this situation because it reflects an unambiguous trade-
off between costs and health outcomes [59,63].
One-Way Sensitivity Analyses
POC-CD4 results in improved clinical outcomes and remains
cost-effective when compared to LAB-CD4 under a wide range of
conditions in one-way sensitivity analyses (Figure 3). Clinical
outcomes improve compared to LAB-CD4 as long as overall
linkage increases with POC-CD4, which could result if test
completion is $50%, receipt of results is $60%, or initiation of
clinical care is $49% as a weighted average of ART-eligible and -
ineligible patients. POC-CD4 remains cost-effective compared to
LAB-CD4, even when the cost of the point-of-care test is far greater
than currently reported. POC-CD4 is no longer cost-effective only
when repeat HIV testing or immunologic staging for those patients
who remain unlinked occurs every 9 mo or more frequently.
Figure 2. Test characteristics of the point-of-care CD4 test as determined by model output. At the time of HIV diagnosis and
immunologic staging, the model captures both the ‘‘true CD4 count’’ of the patient and the ‘‘observed CD4 count,’’ or CD4 test result. The observed
CD4 test result has variability around the true CD4 count, depending on the test itself (e.g., point-of-care CD4 test with precision of 32.6% CV). (A)
Using model output, we calculate the sensitivity (i.e., observed CD4 count #250/ml, true CD4 count #250/ml) and specificity (i.e., observed CD4 count
.250/ml, true CD4 count .250/ml) for point-of-care CD4 tests when policy sets ART eligibility at CD4 count #250/ml. (B) In a scenario in which ART
eligibility is at CD4 count #350/ml, we use model output to calculate the sensitivity (i.e., observed CD4 count #350/ml, true CD4 count #350/ml) and
specificity (i.e., observed CD4 count .350/ml, true CD4 count.350/ml) for point-of-care CD4 tests.
doi:10.1371/journal.pmed.1001725.g002
Table 2. Input parameters for probabilistic sensitivity analysis of immunological staging by POC-CD4 versus LAB-CD4 in
Mozambique.
Variable Distribution Base Case Value SD Reference
Repeat HIV testing or immunologic staging (years) Log-normal 10 4.8 Assumption
Cost per point-of-care CD4 test (US dollars) Log-normal 24 6 [39,40]
Overall linkage to care after POC-CD4 (percent)
a Beta 61 9.8 Adapted from [14]
Annual routine care costs ratio (percent)
b Log-normal 100 25 Adapted from [46]
Mean CD4 at diagnosis (cells/ml) Log-normal 300 150 [14]
Point-of-care test CV (percent)
c Beta 32.6 10 [36]
Linkage after WHO stage 3 or 4 OI (percent) Beta 75 12.5 Assumption
Mean age at diagnosis (years) Log-normal 32.7 7.5 [14]
Linkage after TB (percent) Beta 43 10 [33,34]
aOverall linkage is varied using point-of-care test completion (83%, SD 13.5%).
bAnnual routine care costs for patients with CD4 count #250/ml are US$250 (SD US$62.5), and for patients with CD4 count.250/ml are US$160 (SD US$40).
cPoint-of-care test sensitivity (87%–95%) and specificity (76%–96%).
doi:10.1371/journal.pmed.1001725.t002
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CD4 might be attenuated if higher rates of loss to follow-up result
after linkage with POC-CD4 compared with LAB-CD4. When the
monthly probability of loss to follow-up is higher among patients
who link to care via POC-CD4 (monthly probability, 0.02–0.003)
than among those who link to care via LAB-CD4 (monthly
probability, 0.01–0.002), then the percentage of the cohort who
experiences one or more interruptions in care increases from
30.0% (LAB-CD4) to 45.5% (POC-CD4), and clinical outcomes
are equivalent (discounted life expectancy, 9.6 y). When POC-
CD4 includes an increased rate of loss to follow-up among ART-
ineligible patients (monthly probability, 0.02 for all ART-ineligible
patients with POC-CD4; therefore, 49.8% of patients experience
LTFU), clinical outcomes are worse with POC-CD4 (discounted
life expectancy, 9.4 y) compared to LAB-CD4 (discounted life
expectancy, 9.6 y).
Sensitivity Analysis for CD4 Test Characteristics
POC-CD4 results in better clinical outcomes and is cost-
effective compared with LAB-CD4 even at reduced point-of-care
test sensitivity (82%) and specificity (65%), which can result from
either poor precision or extreme bias (Table 4). Such values are far
below those published [36,38,52]. If the point-of-care CD4 test
operates with perfect sensitivity and specificity, the ICER of POC-
CD4 compared to LAB-CD4 is US$470/YLS, which reflects the
increased rates of linkage with POC-CD4 and represents the cost-
effectiveness ratio for ART in Mozambique. When laboratory
CD4 tests operate with less precision or more bias (i.e., no longer a
‘‘perfect test’’), then POC-CD4 becomes even more cost-effective
compared to LAB-CD4 (ICER, US$460–US$500/YLS) (Fig-
ure 3).
Probabilistic Sensitivity Analysis
When varying nine parameters based on their prespecified
probability distributions (Table 2), POC-CD4 is more cost-
effective than LAB-CD4 92% of the time at the willingness-to-
pay threshold of US$570/YLS, or the Mozambique 2011 per
capita GDP. The probability of POC-CD4 being more cost-
effective than LAB-CD4 is even greater at higher willingness-to-
pay thresholds.
Scenario Analyses
Regional access to care. In settings where access to care
provides fewer opportunities to test and link to care, POC-CD4
leads to a greater increase in 5-y survival than LAB-CD4. For
instance, as shown in Figure 4A, 2.3% of deaths (red) are averted
at 5 y with POC-CD4 compared to LAB-CD4 in a setting with
greater access (Figure 4A, far left column), but 8.1% of deaths
(yellow) are averted if POC-CD4 is used in a setting with less
access to care (Figure 4A, far right column). The clinical benefits
of POC-CD4 increase as POC-CD4 linkage improves, reflected in
an increased percentage of deaths averted (Figure 4A, ascending
the vertical axis). Where regional access to care is less robust,
POC-CD4 becomes more cost-effective compared to LAB-CD4,
as long as linkage to care with POC-CD4 is better than with LAB-
CD4 (Figure 4C). POC-CD4 ceases to be clinically preferred or
cost-effective compared to LAB-CD4 only when POC-CD4
improves linkage by ,5% in settings where repeat HIV testing
occurs at least every 5 y and diagnosis with an OI always leads to
linkage to HIV care (Figure 4A and 4C, far left column).
ART eligibility at CD4 count #350/ml. At an alternative
ART-eligibility threshold of CD4 count #350/ml, 5-y survival
increases to 61.5% with use of LAB-CD4 and 65.1% with POC-
CD4. The discounted life expectancy increases to 9.8 y with LAB-
CD4; POC-CD4 further improves life expectancy to 10.4 y. Per
person discounted lifetime costs are also greater with the
alternative ART-eligibility threshold (LAB, US$2,570; POC,
US$2,900), resulting in an ICER of US$530/YLS for POC-
CD4 compared to LAB-CD4. As linkage after point-of-care CD4
tests improves, POC-CD4 is clinically preferred and more cost-
effective compared to LAB-CD4 in settings where access to repeat
testing and linkage to care is less available (Figure 4B and 4D).
Programmatic Considerations and Affordability
For the 120,000 newly diagnosed patients in Mozambique in 1
y, we estimate that the MMOH and other donors would pay
US$600,000 for immunologic staging with LAB-CD4, which
would increase to US$2,400,000 with POC-CD4. Taking into
account the undiscounted costs of follow-up HIV care for those
patients who successfully link, the MMOH and other donors
would fund US$78.2 million for LAB-CD4 compared to US$94.1
million for POC-CD4 over 5 y. The costs associated with
immunological staging itself are a very small proportion of the
overall 5-y costs (LAB-CD4 0.8%; POC-CD4 2.5%); most of the
increased costs are related to clinical care and ART for the
patients who link to care.
Discussion
Using a simulation model of HIV disease, we find that a POC-
CD4 strategy of immunological staging results in nearly one full
year of additional life expectancy compared to LAB-CD4 and is
near the very cost-effective threshold in Mozambique. To remain
conservative regarding any benefit of POC-CD4, we use the
published estimates of point-of-care CD4 test characteristics and
costs that are among the least favorable. The value of POC-CD4
compared to LAB-CD4 will likely be even greater if point-of-care
Table 3. Base case results of POC-CD4 versus LAB-CD4 for immunologic staging for HIV-infected persons in Mozambique.
Strategy
5-y Survival
(Percent) (95% CI) Lifetime Cost (US Dollars) Life Expectancy (Years)
ICER (US Dollars/YLS)
(95% CI)
Undiscounted
(95% CI)
Discounted
(95% CI)
Undiscounted
(95% CI)
Discounted
(95% CI)
LAB-CD4 60.9 3,930 2,440 14.0 9.6 —
(60.9–61.0) (3,920–3,940) (2,440–2,450) (14.0–14.0) (9.6–9.6)
POC-CD4 65.0 4,460 2,800 15.2 10.3 500
(64.9–65.1) (4,450–4,470) (2,790–2,800) (15.2–15.2) (10.3–10.3) (480–520)
doi:10.1371/journal.pmed.1001725.t003
Cost-Effectiveness of Point-of-Care CD4 Tests
PLOS Medicine | www.plosmedicine.org 8 September 2014 | Volume 11 | Issue 9 | e1001725CD4 tests operate with improved test characteristics [53] or lower
cost [39], or if laboratory-based CD4 tests operate with less than
perfect test characteristics. The majority of costs are due to the
clinical care provided after linkage to care; as the costs of care
decrease, the relative value of POC-CD4 increases compared to
LAB-CD4.
POC-CD4 results in better clinical outcomes and is at the
very cost-effective threshold compared to LAB-CD4 if POC-
CD4 leads to enhanced linkage; much of this improvement is
due to increased test completion and receipt of results. Attention
must therefore remain focused on sustaining improvements in
any of the sequential steps of linkage after POC-CD4 [15,64].
Settings in sub-Saharan Africa with robust transport and
centralized laboratory systems already in place might invest to
improve LAB-CD4 as an alternative approach for improving
patient outcomes. However, the costs of improving transport
and infrastructure could well outpace the costs associated with
POC-CD4, which could also be implemented more quickly to
assist in rapid scale-up.
Although performance characteristics should be a high priority
with any new diagnostic test, our analysis suggests that the impact
of point-of-care CD4 tests on linkage outweighs the effect of the
tests’ performance characteristics within reasonable ranges.
Because the goal of immunological staging is to expedite linkage
to care for those most in need, a POC-CD4 strategy with some
misclassified test results can still lead to improved clinical
outcomes, if overall linkage is better than with LAB-CD4 and if
ART programs can incorporate new ART-eligible patients
promptly.
Our results hold in a diversity of conditions. The more expensive
POC-CD4 strategy still offers excellent value under a wide range of
plausible scenarios that represent a variety of settings in sub-
Saharan Africa, including a range of linkage rates, opportunities for
subsequent accessto care, and loss to follow-up. However, this value
is realized only if ART is available for those patients who link to
care, if patients remain in care, and if sufficient and sustainable
funds are available for a lifetime of clinical care.
As with many cost-effectiveness models, there is a fundamental
assumption about what constitutes cost-effective care. We apply
the WHO-CHOICE standard that uses per capita GDP as a
threshold. Mozambique stands in the lowest tertile of per capita
GDP reported in sub-Saharan Africa (US$570; range, US$220–
US$12,400). In considering the generalizability of these results to
other sub-Saharan countries with greater capacity to pay for
lifesaving care (e.g., Angola or Botswana, with per capita GDPs of
US$5,300 and US$9,500, respectively), POC-CD4 will likely
remain an attractive option over an even wider range of input
value assumptions.
Figure 3. Tornado diagram of one-way sensitivity analyses when ART-eligibility threshold is at CD4 count #250/ml. A range of
parameters varied in one-way sensitivity analyses are displayed on the vertical axis. The ICER (US dollars/YLS) of POC-CD4 compared to LAB-CD4 is
represented on the x-axis. The solid vertical line indicates the ICER of the base case (US$500/YLS). The dashed vertical line represents the per capita
GDP of Mozambique (MOZ GDP), i.e., the ‘‘very cost-effective’’ threshold; the dotted vertical line represents three times GDP, i.e., the ‘‘cost-effective’’
threshold. For each parameter, the horizontal bar represents the range of ICERs that result from varying that parameter along the range of values
indicated in the parentheses; the first value listed in the parentheses is the one that results in the lowest ICER. Of all one-way sensitivity analyses, the
ICER of POC-CD4 compared to LAB-CD4 crosses the cost-effectiveness threshold (into the area of not being cost-effective) (US$1,710/YLS) only when
point-of-care CD4 test cost is.US$1,100/test or when repeat HIV testing or immunologic staging are completed every 9 mo or more frequently.
doi:10.1371/journal.pmed.1001725.g003
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PLOS Medicine | www.plosmedicine.org 10 September 2014 | Volume 11 | Issue 9 | e1001725Despite its good value, POC-CD4 is not without cost. We
estimate an additional US$1,800,000 duetopoint-of-careCD4tests
in the first year of use, if 120,000 patients are eligible for
immunological staging. An overwhelming majority of the increased
costs associated with POC-CD4 over 5 y (88.7% of the US$15.9
million) are due not to the test itself, but rather to the downstream
costs (e.g., ART and clinical visits) associated with an increased
numberofpeopleengaged inHIVclinicalcare.Suchcostswouldbe
incurred for any patients who link to care, regardless of method of
linkage (e.g., POC-CD4). Given the annual budget of more than
US$146 million for HIV care funded by Mozambique and donors
[60], our analysis suggests that POC-CD4 is a feasible option
because the increased associated costs represent 2.2% of what is
currently spent on the AIDS response in Mozambique.
While some argue that the most resource-constrained settings
cannot afford the cost of POC-CD4, our results indicate that this is
likely where the greatest value lies. Our findings support the use of
POC-CD4 particularly in settings where alternative opportunities
for linkage to care are limited or other interventions have failed.
The comparative value of POC-CD4 compared to LAB-CD4 at
VCT clinics may be less if other strategies are also used to enhance
subsequent linkage to HIV care after an initial failure to link,
including home-based testing and linkage to care [65], mobile
clinics [66], mHealth technologies [67], peer navigators [68–70],
or decentralization of HIV clinical care [71]. Our results
underscore that the opportunity to access care after HIV diagnosis
is an important indicator of resource limitation and could guide
where POC-CD4 implementation would be of greatest value.
According to the nationwide registry of CD4 testing in the national
health service (I. V. J.), 22% of CD4 tests in the public sector are
now being performed using POC-CD4 in Mozambique, with site
selection focused on areas with poor access to existing laboratories.
Figure 4. Multi-way sensitivity analysis on regional access to care and linkage to care with POC-CD4 compared to LAB-CD4.
Projected decrease in 5-y mortality and ICERs with use of POC-CD4 compared to LAB-CD4 in four settings that represent a range of access to care
(decreasing access to care from left to right) and with different probabilities of linkage with POC-CD4 (increasing up the vertical axis). The base case is
indicated by the X in each figure; the horizontal lines represent the base case overall linkage rates (POC-CD4, solid black; LAB-CD4, dashed white).
Decreased mortality at 5 y with POC-CD4 is projected in settings that use current Mozambique guidelines for ART eligibility (CD4 count #250/ml) (A)
or earlier ART eligibility (CD4 count #350/ml) (B). More deaths could be averted (noted by changes in color towards green) in settings with fewer
opportunities to access care or by improving POC-CD4 linkage rates compared to LAB-CD4. Blue denotes the few situations in which LAB-CD4 results
in better clinical outcomes than POC-CD4 at 5 y. (C) displays the ICERs of POC-CD4 compared with LAB-CD4 given current Mozambique guidelines
(ART eligibility at CD4 count #250/ml); (D) displays ICERs in settings with earlier ART eligibility (CD4 count #350/ml). POC-CD4 is at the very cost-
effective threshold (i.e., US$450–US$860/YLS in [C] and US$460–US$1,030/YLS in [D]) compared to LAB-CD4 except when linkage with POC-CD4 is ,
5% better than LAB-CD4 in settings with repeat HIV testing every 5 y.
doi:10.1371/journal.pmed.1001725.g004
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PLOS Medicine | www.plosmedicine.org 11 September 2014 | Volume 11 | Issue 9 | e1001725Because each country in sub-Saharan Africa includes a diversity of
settings for access to care, the value of POC-CD4 implementation
could be maximized by targeting specific settings where opportu-
nities for subsequent linkage are least available.
This analysis has several limitations. We do not address the use
of point-of-care CD4 tests for routine monitoring [72]. In cases
where point-of-care testing will repeatedly influence clinical
management, poor test characteristics and increased cost of a
point-of-care test could have a greater impact on clinical outcomes
and lifetime costs. Although POC-CD4 costs include estimates for
labor, quality control, etc., a more comprehensive rollout of POC-
CD4 could reveal additional operational challenges such as
instrument or operator failure, which could further reduce the
efficacy or increase the costs of POC-CD4 compared to LAB-
CD4. In our simulation, we do not directly assess the POC-CD4
impact of increasing ART coverage on reducing HIV transmis-
sions [73]. However, the incorporation of any decreased
transmissions due to earlier ART initiation resulting from POC-
CD4 into this model-based analysis would further increase the
value of POC-CD4 compared with LAB-CD4.
Too many eligible patients still await ART initiation. It is
important to identify cost-effective methods for immunologic
staging that will expedite access to care for the high-priority cases
of the most immunosuppressed individuals throughout sub-
Saharan Africa. Point-of-care CD4 tests are now available, and
a growing body of evidence supports improved overall linkage to
care with their use. We find that a POC-CD4 strategy can avert
deaths and offers excellent value for immunologic staging
compared to LAB-CD4 across a wide range of parameters in
Mozambique, as well as in a diversity of resource-limited settings.
Despite a modest increase in costs, POC-CD4 could remain
economically efficient and have the greatest impact on mortality in
settings throughout sub-Saharan Africa, where health care
resources and systems are the most limited.
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Background. AIDS has already killed about 36 million
people, and a similar number of people (mostly living in low-
and middle-income countries) are currently infected with
HIV, the virus that causes AIDS. HIV destroys immune system
cells (including CD4 cells, a type of lymphocyte), leaving
infected individuals susceptible to other infections. Early in
the AIDS epidemic, HIV-infected individuals usually died
within ten years of infection. After effective antiretroviral
therapy (ART) became available in 1996, HIV infection
became a chronic condition for people living in high-income
countries, but because ART was expensive, HIV/AIDS
remained a fatal disease in low- and middle-income
countries. In 2003, the international community began to
work towards achieving universal ART coverage, and by the
end of 2012, 61% of HIV-positive people (nearly 10 million
individuals) living low- and middle-income countries who
were eligible for treatment—because their CD4 cell count
had fallen below 350 cells/mm
3 of blood or they had
developed an AIDS-defining condition—were receiving
treatment.
Why Was This Study Done? In sub-Saharan Africa nearly
50% of HIV-infected people eligible for treatment remain
untreated, in part because of poor linkage between HIV
diagnosis and clinical care. After patients receive a diagnosis
of HIV infection, their eligibility for ART initiation is
determined by sending a blood sample away to a laboratory
for a CD4 cell count (the current threshold for treatment is a
CD4 count below 500/mm
3, although low- and middle-
income countries have yet to update their national guide-
lines from the threshold CD4 count below 350/mm
3).
Patients have to return to the clinic to receive their test
results and to initiate ART if they are eligible for treatment.
Unfortunately, many patients are ‘‘lost’’ during this multistep
process in resource-limited settings. Point-of-care CD4 tests
at HIV diagnosis—tests that are done on the spot and
provide results the same day—might help to improve
linkage to care in such settings. Here, the researchers use a
mathematical model to assess the clinical outcomes and
cost-effectiveness of point-of-care CD4 testing at the time of
HIV diagnosis compared to laboratory-based testing in
Mozambique, where about 1.5 million HIV-positive individ-
uals live.
What Did the Researchers Do and Find? The researchers
used a validated model of HIV testing, linkage, and treatment
called the Cost-Effectiveness of Preventing AIDS Complica-
tions–International (CEPAC-I) model to compare the clinical
impact, costs, and cost-effectiveness of point-of-care and
laboratory CD4 testing in newly diagnosed HIV-infected
patients in Mozambique. They used published data to
estimate realistic values for various model input parameters,
including the probability of linkage to care following the use
of each test, the accuracy of the tests, and the cost of each
test. At a CD4 threshold for treatment of 250/mm
3, the
model predicted that 60.9% of newly diagnosed HIV-infected
people would survive five years if their immunological status
was assessed using the laboratory-based CD4 test, whereas
65% would survive five years if the point-of-care test was
used. Predicted life expectancies were 9.6 and 10.3 years
with the laboratory-based and point-of-care tests, respec-
tively, and the per person lifetime costs (which mainly reflect
treatment costs) associated with the two tests were
US$2,440 and $US2,800, respectively. Finally, the incremental
cost-effectiveness ratio—calculated as the incremental costs
of one therapeutic intervention compared to another
divided by the incremental benefits—was US$500 per year
of life saved, when comparing use of the point-of-care test
with a laboratory-based test.
What Do These Findings Mean? These findings suggest
that, compared to laboratory-based CD4 testing, point-of-
care testing at HIV diagnosis could improve survival for HIV-
infected individuals in Mozambique. Because the per capita
gross domestic product in Mozambique is US$570, these
findings also indicate that point-of-care testing would be
very cost-effective compared to laboratory-based testing (an
incremental cost-effectiveness ratio less than one times the
per capita gross domestic product is regarded as very cost-
effective). As with all modeling studies, the accuracy of these
findings depends on the assumptions built into the model
and on the accuracy of the input parameters. However, the
point-of-care strategy averted deaths and was estimated to
be cost-effective compared to the laboratory-based test over
a wide range of input parameter values reflecting Mozam-
bique and several other resource-limited settings that the
researchers modeled. Importantly, these ‘‘sensitivity analy-
ses’’ suggest that point-of-care CD4 testing is likely to have
the greatest impact on HIV-related deaths and be econom-
ically efficient in settings in sub-Saharan Africa with the most
limited health care resources, provided point-of-care CD4
testing improves the linkage to care for HIV-infected people.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001725.
N The World Health Organization provides information on all
aspects of HIV/AIDS (in several languages); its
‘‘Consolidated Guidelines on the Use of Antiretroviral
Drugs for Treating and Preventing HIV Infections:
Recommendations for a Public Health Approach’’, which
highlights the potential of point-of-care tests to improve
the linkage of newly diagnosed HIV-infected patients to
care, is available
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N NAM/aidsmap provides basic information about HIV/AIDS,
and summaries of recent research findings on HIV care and
treatment; it has a fact sheet on CD4 testing
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on starting, monitoring, and switching treatment and
on HIV and AIDS in sub-Saharan Africa (in English and
Spanish)
N The ‘‘UNAIDS Report on the Global AIDS Epidemic 2013’’
provides up-to-date information about the AIDS epidemic
and efforts to halt it
N Personal stories about living with HIV/AIDS are available
through Avert, Nam/aidsmap, and Healthtalkonline
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